Publication Date:
2015-12-19
Description:
Middle East respiratory syndrome coronavirus (MERS-CoV) infections have led to an ongoing outbreak in humans, which was fueled by multiple zoonotic MERS-CoV introductions from dromedary camels. In addition to the implementation of hygiene measures to limit further camel-to-human and human-to-human transmissions, vaccine-mediated reduction of MERS-CoV spread from the animal reservoir may be envisaged. Here we show that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels. Compared with results for control animals, we observed a significant reduction of excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge. Protection correlated with the presence of serum neutralizing antibodies to MERS-CoV. Induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Haagmans, Bart L -- van den Brand, Judith M A -- Raj, V Stalin -- Volz, Asisa -- Wohlsein, Peter -- Smits, Saskia L -- Schipper, Debby -- Bestebroer, Theo M -- Okba, Nisreen -- Fux, Robert -- Bensaid, Albert -- Solanes Foz, David -- Kuiken, Thijs -- Baumgartner, Wolfgang -- Segales, Joaquim -- Sutter, Gerd -- Osterhaus, Albert D M E -- New York, N.Y. -- Science. 2016 Jan 1;351(6268):77-81. doi: 10.1126/science.aad1283. Epub 2015 Dec 17.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands. b.haagmans@erasmusmc.nl gerd.sutter@lmu.de albert.osterhaus@tiho-hannover.de. ; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands. ; German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. ; Department of Pathology, University of Veterinary Medicine, Hannover, Germany. ; Institut de Recerca i Tecnologia Agroalimentaries (IRTA), Centre de Recerca en Sanitat Animal [CReSA, IRTA-Universitat Autonoma de Barcelona (UAB)], Campus de la UAB, 08193 Bellaterra, Spain. ; UAB, CReSA, (IRTA-UAB), Campus de la UAB, 08193 Bellaterra, Spain. Departament de Sanitat i Anatomia Animals, Facultat de Veterinaria, UAB, 08193 Bellaterra, Spain. ; German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. b.haagmans@erasmusmc.nl gerd.sutter@lmu.de albert.osterhaus@tiho-hannover.de. ; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands. Artemis One Health, Utrecht, Netherlands. Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine, Hannover, Germany. b.haagmans@erasmusmc.nl gerd.sutter@lmu.de albert.osterhaus@tiho-hannover.de.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/26678878" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Antibodies, Neutralizing/blood/immunology
;
Antibodies, Viral/blood/immunology
;
Camels/*virology
;
Coronavirus Infections/*prevention & control/*veterinary
;
Disease Outbreaks/*prevention & control
;
Humans
;
Middle East Respiratory Syndrome Coronavirus/*physiology
;
RNA, Viral/immunology
;
Spike Glycoprotein, Coronavirus/genetics/*immunology
;
Vaccinia virus/genetics/*immunology
;
Viral Vaccines/*immunology
;
Virus Shedding/immunology
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink